Quest Diagnostics Incorporated is the world's leading provider of diagnostic information services, reporting $11.04 billion in revenue for fiscal year 2025 while processing over 220 million diagnostic requisitions annually and maintaining clinical laboratory data on more than 65% of the U.S. population. Founded in 1967 by Dr. Paul A. Brown as Metropolitan Pathology Laboratory in Teaneck, New Jersey, the company has grown through decades of strategic acquisitions into an enterprise employing approximately 50,000 people and serving one in three adult Americans each year. Quest Diagnostics trades on the NYSE under ticker DGX with a market capitalization of approximately $18-20 billion.
Quest Diagnostics: Key Facts
- Founded: 1967 in Teaneck, New Jersey
- Headquarters: Secaucus, New Jersey
- CEO: Jim Davis (Chairman, CEO, and President since November 2022)
- 2025 Revenue: $11.035 billion (up 11.8% from 2024)
- 2025 Operating Income: $1.556 billion (up 15.6%)
- 2025 Net Income: $992 million (up 13.9%)
- 2025 Adjusted Diluted EPS: $9.85 (up 10.3%)
- Employees: Approximately 50,000 (nearly 57,000 including LifeLabs)
- Patient Service Centers: 2,200+ locations
- Annual Requisitions: 220+ million
How Does Quest Diagnostics Make Money?
Quest Diagnostics generates revenue primarily through clinical laboratory testing services. The company collects biological specimens from patients through over 2,200 patient service centers, physician offices, and hospital partnerships; transports them to regional and national laboratories for analysis; and delivers diagnostic results to physicians and patients. The Diagnostic Information Services segment generated $10.785 billion (97.7% of 2025 revenue).
Revenue is driven by two metrics: requisition volume and revenue per requisition. In 2025, requisition volume grew 12.3% while revenue per requisition was flat (up 0.1%), demonstrating that growth is volume-driven rather than price-driven. Revenue is reimbursed by Medicare, Medicaid, commercial insurance, and direct patient payments. Higher-margin advanced diagnostics in oncology (Haystack MRD), neurology (AD-Detect Alzheimer's tests), genomics (Blueprint Genetics), and cardiometabolic health represent the fastest-growing categories. Consumer-initiated testing through QuestDirect generates direct payments at list price with the highest margins.
Who Founded Quest Diagnostics and When?
Quest Diagnostics was founded in 1967 by Dr. Paul A. Brown as Metropolitan Pathology Laboratory in Teaneck, New Jersey. Brown, a pathologist, established the laboratory to provide clinical pathology and anatomic pathology services to local physicians and hospitals. The company was renamed MetPath, Inc. in 1969. In 1982, Corning Glass Works acquired MetPath and renamed it Corning Clinical Laboratories. On December 31, 1996, Quest Diagnostics became an independent public company through a spin-off from Corning and began trading on the NYSE under ticker DGX.
The transformative 1999 acquisition of SmithKline Beecham Clinical Laboratories for $1.3 billion doubled the company's size and established it as the industry leader. Under CEO Steve Rusckowski (2012-2022), Quest focused on operational excellence, health system partnerships, and growth initiatives including advanced diagnostics and consumer testing. Jim Davis became CEO in November 2022 and has accelerated acquisitions and advanced diagnostics focus.
What Is Quest Diagnostics' Competitive Advantage?
Quest Diagnostics' most defensible competitive moat is its clinical laboratory database—the largest in the world—with data on over 65% of the U.S. population. This data asset enables population health analytics, pharmaceutical research collaborations, public health surveillance, and predictive health insights that no competitor can replicate. The company collaborates with the CDC and state health departments on disease outbreak detection.
The national network of 2,200+ patient service centers provides geographic coverage and convenience that regional labs cannot match. The esoteric and advanced diagnostics capabilities—AD-Detect Alzheimer's tests, Haystack Oncology MRD platform, Blueprint Genetics rare disease testing—create differentiation in high-margin categories. The hospital outreach acquisition model (NewYork-Presbyterian, Memorial Hermann, Hackensack Meridian) provides captive patient volumes and institutional credibility.
How Has Quest Diagnostics' Revenue Grown Over Time?
Quest Diagnostics' revenue trajectory reflects acquisition-driven growth and volume expansion. The company reported $7.53 billion in 2018, $7.73 billion in 2019, $9.44 billion in 2020 (boosted by COVID-19 testing), $10.79 billion in 2021, $9.88 billion in 2022 (COVID normalization), $9.25 billion in 2023, $9.87 billion in 2024, and $11.04 billion in 2025. The 2025 growth was driven by the LifeLabs acquisition (closed August 2024), organic volume growth of 3.4%, and advanced diagnostics expansion.
The revenue story is one of steady growth punctuated by the COVID-19 pandemic boom and normalization. The company's ability to grow revenue 11.8% in 2025 while maintaining 15.9% adjusted operating margins demonstrates successful execution of the growth strategy.
Quest Diagnostics Business Model Explained
Quest Diagnostics operates a clinical laboratory services model that functions on scale economies and fixed-cost infrastructure leverage. The company collects specimens, transports them to laboratories, performs analyses using automated and specialized instrumentation, and delivers results electronically. Cost of services was $7.37 billion in 2025 (66.8% of revenue), with selling, general, and administrative expenses of $1.97 billion (17.8%).
The business model has three defining characteristics. First, operating leverage: as more specimens flow through fixed laboratory infrastructure, incremental margins improve. The 11.8% revenue increase in 2025 generated a 15.6% operating income increase. Second, payer mix dependency: Medicare, Medicaid, and commercial insurance reimbursement rates determine profitability, with Medicare PAMA-implemented fee schedules creating downward pricing pressure. Third, volume-driven growth: with revenue per requisition essentially flat, all growth must come from requisition volume expansion through acquisitions, market share gains, and new test offerings.
Quest Diagnostics Key Acquisitions
Quest Diagnostics' most recent and significant acquisition is LifeLabs, completed in August 2024 for CAD $1.35 billion (USD ~$1 billion). LifeLabs is Canada's leading laboratory provider with 6,500+ employees, 8+ million online portal users, and approximately CAD $970 million in annual revenue. The acquisition established Quest as the dominant lab provider in Canada.
Other transformative acquisitions include SmithKline Beecham Clinical Laboratories ($1.3 billion, 1999), which doubled the company's size; AmeriPath ($1.23 billion, 2007), adding anatomic pathology; Unilab ($800 million, 2003), expanding West Coast presence; and Solstas Lab Partners ($570 million, 2014). Recent acquisitions include Haystack Oncology (2023, MRD testing), NewYork-Presbyterian outreach lab ($275 million, 2023), and Spectra Laboratories assets from Fresenius Medical Care (2025, renal testing).
What Are the Biggest Risks Facing Quest Diagnostics?
The biggest risk is the combination of reimbursement compression and regulatory uncertainty in a business with structurally limited pricing power. PAMA-mandated Medicare fee schedule reductions have cut reimbursement for common tests, and commercial payers follow Medicare trends. Revenue per requisition grew only 0.1% in 2025. The FDA's potential regulation of laboratory-developed tests (LDTs) as medical devices could increase compliance costs and delay launches for high-margin advanced diagnostics. Healthcare labor wage inflation affects cost-intensive operations. The competitive duopoly with LabCorp requires continuous investment without pricing power. If volume growth slows, the operating leverage that drives profitability could reverse.
Bottom Line
Quest Diagnostics is executing one of healthcare's most compelling growth strategies. The company reported record 2025 results with $11.04 billion in revenue (up 11.8%), $1.56 billion in operating income (up 15.6%), and $1.89 billion in cash from operations (up 41.4%). The LifeLabs acquisition established Canadian dominance, while AD-Detect Alzheimer's tests and Haystack Oncology MRD testing position Quest at the forefront of multi-billion dollar diagnostic markets. The three-pillar strategy—core diagnostic growth through hospital outreach, advanced diagnostics expansion, and consumer-initiated testing—is generating measurable results. The 2026 guidance raise and dividend increase reflect management confidence. The key risks are reimbursement pressure and regulatory uncertainty, but the structural tailwinds of an aging population, chronic disease prevalence, and diagnostic innovation favor continued growth. Quest Diagnostics is evolving from a 'test-and-report' laboratory into a 'test-and-insight' health intelligence platform—and the 2025-2027 period will determine whether the market values this evolution.
